To advance the development of δ-tocotrienol into phase II clinical trials, the molecular targets that play a central role in δ-tocotrienol efficacy in pancreatic cancer need to be elaborated so that they can be used as biomarkers of p27Kip1 efficacy. The gene discussed is CDKN1B; the disease is familial pancreatic carcinoma.